Tue, Sep 16, 2014, 5:40 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

PLC Systems Inc. Message Board

  • n8rlvr45 n8rlvr45 Sep 23, 2010 10:13 AM Flag

    Good News Today!

    MYTHOS RenalGuard® Trial Demonstrates Greater Efficacy Than Current Standard of Care. Here's the link.

    http://finance.yahoo.com/news/MYTHOS-RenalGuard-Trial-prnews-3469204284.html?x=0&.v=1

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yes, very good news; but generally anticipated, given previous study results. But for stock to move up, we need a deal to sell rights of RenalG, or a partnership, or a cash investor.
      And, boy would it be great with there were a process by which US approval for use of RG could be granted based on the exhaustive and extensive Italian studies--even on a temporary or conditional basis. Since its only a device and a procedure and not a medicine, it would make sense if there were a side-step method for a US approval based on efficacy and safety demonstrated in these studies. But, if there were, I'd guess we would have heard in past CC's for such a plan by PLC should the study results prove as successful as they had.

      • 1 Reply to participant42
      • Yeah, in general, the first device of a class has fairly serious testing requirements. I'm not at all sure if PLC's patent estate gives them any hope of collecting royalties should someone implement the idea by adding an extra nurse (You might want to do this despite the outsize cost just for the effectiveness) (But I think it does).

        With the Italian results being so dramatic, you could plan a fairly small pivotal US study, which saves money. There were probably individuals at that conference who could swing that much personally. But that would still leave PLC hopelessly backward in US selling muscle. So best hope is still a big friend to take over the project.

 
PLCSF
0.015-0.004(-21.05%)Sep 16 3:57 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.